A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer

[1]  Toshiharu Yamaguchi,et al.  A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. , 2005, Anticancer research.

[2]  A. Ohtsu,et al.  Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer , 2003, British Journal of Cancer.

[3]  A. Roth.  Chemotherapy in gastric cancer: a never ending saga. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Ajani,et al.  Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995–2001 , 2002, International Journal of Clinical Oncology.

[5]  H. Lenz,et al.  Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. , 2001, Japanese journal of clinical oncology.

[6]  M. Kurihara,et al.  Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer , 2000, Oncology.

[7]  M. Kurihara,et al.  Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. , 2000, Oncology.

[8]  Y. Maehara,et al.  An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers , 1999, Oncology.

[9]  K. Gelmon,et al.  A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  K. Sugimachi,et al.  Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. , 1998, European journal of cancer.

[11]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Ajani,et al.  Phase II study of Taxol in patients with advanced gastric carcinoma. , 1998, The cancer journal from Scientific American.

[13]  I. Dimery,et al.  Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule. , 1997, Seminars in oncology.

[14]  S. Cascinu,et al.  A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. , 1997, European journal of cancer.

[15]  K. Adachi,et al.  Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. , 1996, British Journal of Cancer.

[16]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[17]  E. Eisenhauer,et al.  Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  D. Wagener,et al.  Chemotherapy of gastric cancer. , 1996, Anti-cancer drugs.

[19]  C. Chi,et al.  Paclitaxel‐induced apoptosis in human gastric carcinoma cell lines , 1996, Cancer.

[20]  J. Heimans,et al.  Paclitaxel-induced neuropathy. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J B Vermorken,et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Schiller,et al.  Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Fukushima,et al.  Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. , 1993, Cancer research.

[24]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.